DNA methylation status of dapk and MT1G genes in diffuse large B-cell lympihoma and its clinical relevance /
Samir Ahmed Shawky
DNA methylation status of dapk and MT1G genes in diffuse large B-cell lympihoma and its clinical relevance / دراسة نسق إضافة مركب الميثيل إلى الحامض النووى الديؤكسى ريبوزى فى الجينين (دى أ بى كا) و (م ت ١ جى) فى حالات سرطان الجهاز الليمفاوى (بى) ذو الخلايا الكبيرة و أهميته الأكلينيكية Samir Ahmed Shawky ; Supervised Mohamed H. Elborai , Hussein M. Khaled , Abeer Ahmad Bahnassy - Cairo : Samir Ahmed Shawky , 2012 - 103 P. : charts ; 30cm
This thesis arrived by email without CD
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Pathology
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of of Non-hodgkin's lymphoma (NHL) and can be divided into prognostically important subgroups with germinal center B-cell-like (GCB) and non-GCB subtypes either by using cDNA microarray or immunostains (CD10, BCL6, MUM1). Beyond genetic alterations, identification of novel epigenetic alterations, such as aberrant methylation may yield better diagnostic, prognostic and therapeutic information
DAPK MT1G Promotor hypermethylation
DNA methylation status of dapk and MT1G genes in diffuse large B-cell lympihoma and its clinical relevance / دراسة نسق إضافة مركب الميثيل إلى الحامض النووى الديؤكسى ريبوزى فى الجينين (دى أ بى كا) و (م ت ١ جى) فى حالات سرطان الجهاز الليمفاوى (بى) ذو الخلايا الكبيرة و أهميته الأكلينيكية Samir Ahmed Shawky ; Supervised Mohamed H. Elborai , Hussein M. Khaled , Abeer Ahmad Bahnassy - Cairo : Samir Ahmed Shawky , 2012 - 103 P. : charts ; 30cm
This thesis arrived by email without CD
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Pathology
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of of Non-hodgkin's lymphoma (NHL) and can be divided into prognostically important subgroups with germinal center B-cell-like (GCB) and non-GCB subtypes either by using cDNA microarray or immunostains (CD10, BCL6, MUM1). Beyond genetic alterations, identification of novel epigenetic alterations, such as aberrant methylation may yield better diagnostic, prognostic and therapeutic information
DAPK MT1G Promotor hypermethylation